Belching is a common bodily function, but when it escalates to a level that interferes with daily life, it is defined as belching disorders. International surveys have reported that approximately 1% of adults have belching disorders, but the percentage in Japan and the factors involved often elude medical professionals.

To examine the relationship between the rate of belching disorders, comorbidities, and lifestyles in Japan, a research team led by Professor Yasuhiro Fujiwara of Osaka Metropolitan University’s Graduate School of Medicine conducted a web survey of 10,000 adults. The results showed that 1.5%, or 151 people, had belching disorders. This was more prevalent in those who were men, drank alcohol, and were taking acid reflux medications.

Additionally, it was found that the presence of gastrointestinal disease, eating until feeling full, and extremely low or high chewing frequency were significantly associated with the development of belching disorders. Conversely, a high consumption of carbonated beverages had no association.

“The problem with belching disorders is that they take a long time to treat and are only practiced in a limited number of medical facilities,” stated Professor Fujiwara. “In the future, the evaluation of the number of times someone chews and the effects of improved dietary habits in patients with belching disorders will provide a treatment option for patients to perform on their own.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 2 multiplied by 3?

Explore More

Comprehensive guideline on using biomarkers for monitoring Crohn’s disease

The American Gastroenterological Association (AGA) released a new evidence-based guideline recommending the use of blood and stool-based biomarkers to help manage Crohn’s disease, a type of inflammatory bowel disease (IBD).

Hope for millions of IBS sufferers as research identifies cause of pain as ‘gut itch’

This is big news for Irritable Bowel Syndrome (IBS) patients: 11 percent of the world’s population suffers from IBS, but the fight against chronic pain has taken a major step

A novel approach to combat fatty liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as “non-alcoholic fatty liver disease” — affects about 25% of the global population. Its severe form, metabolic dysfunction-associated steatohepatitis (MASH), can